Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Diabet Med ; 30(5): 581-9, 2013 May.
Article in English | MEDLINE | ID: mdl-23210933

ABSTRACT

AIMS: To develop an antibiotic foot formulary for the empirical treatment of diabetes-related foot infections presenting to our service. Subsequently, to asses costs associated with the introduction of our protocol, in particular to assess the effect on admissions avoidance and any cost savings achieved. METHODS: We reviewed several existing antibiotic protocols. We analysed data on costs related to treatment and admission rates prior to and after the introduction of the protocol. RESULTS: We rationalized our antibiotic protocol and adapted the Infectious Disease Society of America guideline by introducing a category of 'moderate infection-borderline admission' to our classification. This enabled the administration of outpatient intramuscular antibiotics. After introducing the rationalized protocol, our average antibiotic prescribing costs for a 3-week course of treatment fell from £17.12 to £16.42. Over 22 months of follow-up, 26 episodes were eligible for treatment with intramuscular antibiotics. Over the same time period, 121 people were admitted directly from the foot clinic. The costs saved as a result of avoided or delayed admission for those 26 episodes was over £76 000. For 12 people who required subsequent admission, their length of hospital stay was significantly shorter than those admitted directly [9.25 days (range 2-25) vs. 16.11 (2-64), P = 0.045]. CONCLUSIONS: By modifying the Infectious Disease Society of America classification and adopting a protocol to administer outpatient oral and intramuscular antibiotics, we have led to substantial cost savings, shorter hospital admissions and also have developed a successful admissions avoidance strategy.


Subject(s)
Ambulatory Care Facilities/economics , Anti-Bacterial Agents/therapeutic use , Cellulitis/drug therapy , Diabetic Foot/drug therapy , Hospitalization/economics , Length of Stay/economics , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Cellulitis/economics , Cellulitis/etiology , Clinical Protocols , Cost-Benefit Analysis , Diabetic Foot/complications , Diabetic Foot/economics , Female , Humans , Injections, Intramuscular , Male , Middle Aged , Practice Guidelines as Topic , Severity of Illness Index , Tertiary Healthcare
4.
Pediatr Dermatol ; 3(1): 75-8, 1985 Nov.
Article in English | MEDLINE | ID: mdl-3877919

ABSTRACT

Histiocytosis X is a disorder of histiocytes of the Langerhans' cell lineage. As the initial feature is often cutaneous, recognition of these skin changes is important. Several cutaneous manifestations have been described, most commonly, seborrheic dermatitis with a hemorrhagic component. We saw two patients with histiocytosis X with cutaneous manifestations resembling cherry angiomas.


Subject(s)
Hemangioma/pathology , Histiocytosis, Langerhans-Cell/pathology , Adult , Child, Preschool , Diagnosis, Differential , Humans , Infant , Male , Middle Aged , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...